Featured news

[2022.10.03] Eligo Bioscience secures additional landmark CRISPR patent

[2022.10.03] Eligo demonstrates for the first time that in situ base editing of the microbiome can be achieved with high efficiency

The human body harbors more than 250 million bacterial genes

The interactions between the gene repertoire of the microbiome and the immune system of the host play a pivotal role in health and disease.

The human body harbors more than 250 million bacterial genes

The interactions between the gene repertoire of the microbiome and the immune system of the host play a pivotal role in health and disease.

microbiome health disease bacteria

The presence or absence of a single bacterial gene can trigger or aggravate a variety of diseasesI

This genetic causality is being demonstrated in a growing number of therapeutic areas

Introducing our GEM (Gene Editing of the Microbiome) platform

A first-in-class proprietary platform to edit the microbiome gene repertoire in vivo

“Eligo’s technology could be as important as the discovery of penicillin.”

– Professor Christian Brechot,
Executive director at Institut Pasteur

world economic forum technology pioneer eligo

duportet MIT TR35 innovator

Led by world-class scientists and founded by the inventors of CRISPR-based bacterial precision killing

Led by world-class scientists and founded by the inventors of CRISPR-based bacterial precision killing

world economic forum technology pioneer eligo

MIT TR35 innovator duportet eligo

We are hiring!

Join Our Team

Our Partners & Investors

bpifrance eligo microbiome funding

institut pasteur eligo bikard duportet microbiome

khosla ventures eligo microbiome

seventure partners funds eligo